Background and Update to a Phase I Trial of Stem Cell Gene Marking in Multiple Myeloma

Alexander Keith Stewart, H. Miles Prince, Ian D. Dubé

Research output: Contribution to journalArticle

Abstract

Attractive target cells in gene transfer approaches to cancer treatment are pluripotent hematopoietic stem cells (HSCs) because of their high proliferative potential, self renewal and the wide systemic distribution of their progeny. A retroviral-mediated approach to gene transfer into HSCs is currently favored because the transduced gene is permanently integrated into the genome of the target cell resulting in the long-term stable expression of the gene product. Unfortunately, this approach requires that the target cell be in cycle and thus retroviral transduction of normally quiescent HSCs generally occurs at low efficiency. In previous work we have demonstrated that reinfused genetically marked long term bone marrow culture cells contribute significantly to long term hematopoiesis in a canine model. If also true in humans, such experiments suggest that bone marrow cells could be removed, transduced with a retroviral vector carrying a gene of known therapeutic effect and reinfused into the autologous recipient with minimal toxicity. The demonstration of successful long term gene transfer in humans would be an important prelude to therapeutic trials using genetically modified cells. To proceed in this new direction, important biological questions about the safety and feasibility of treatment with gene marked cells must first be addressed. We have therefore obtained local institutional review board and Canadian Health Protection Branch approval for a phase I clinical trial which it is hoped will extend our understanding of the behavior of gene marked hematopoietic progenitor cells in vivo. In this trial gene marked autologous marrow cells will be reinfused into volunteer patients undergoing myeloablative treatment for multiple myeloma. In this paper we describe the background to our ongoing trial and provide a trial outline.

Original languageEnglish (US)
Pages (from-to)175-184
Number of pages10
JournalTransfusion and Apheresis Science
Volume17
Issue number1
StatePublished - Mar 1996
Externally publishedYes

Fingerprint

Multiple Myeloma
Stem Cells
Hematopoietic Stem Cells
Genes
Bone Marrow Cells
Pluripotent Stem Cells
Clinical Trials, Phase I
Research Ethics Committees
Hematopoiesis
Therapeutic Uses
Canidae
Volunteers
Therapeutics
Bone Marrow
Genome
Safety
Gene Expression
Health
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Infectious Diseases

Cite this

Background and Update to a Phase I Trial of Stem Cell Gene Marking in Multiple Myeloma. / Stewart, Alexander Keith; Prince, H. Miles; Dubé, Ian D.

In: Transfusion and Apheresis Science, Vol. 17, No. 1, 03.1996, p. 175-184.

Research output: Contribution to journalArticle

@article{2856cd1533b144c0a3f86ef6b1e49574,
title = "Background and Update to a Phase I Trial of Stem Cell Gene Marking in Multiple Myeloma",
abstract = "Attractive target cells in gene transfer approaches to cancer treatment are pluripotent hematopoietic stem cells (HSCs) because of their high proliferative potential, self renewal and the wide systemic distribution of their progeny. A retroviral-mediated approach to gene transfer into HSCs is currently favored because the transduced gene is permanently integrated into the genome of the target cell resulting in the long-term stable expression of the gene product. Unfortunately, this approach requires that the target cell be in cycle and thus retroviral transduction of normally quiescent HSCs generally occurs at low efficiency. In previous work we have demonstrated that reinfused genetically marked long term bone marrow culture cells contribute significantly to long term hematopoiesis in a canine model. If also true in humans, such experiments suggest that bone marrow cells could be removed, transduced with a retroviral vector carrying a gene of known therapeutic effect and reinfused into the autologous recipient with minimal toxicity. The demonstration of successful long term gene transfer in humans would be an important prelude to therapeutic trials using genetically modified cells. To proceed in this new direction, important biological questions about the safety and feasibility of treatment with gene marked cells must first be addressed. We have therefore obtained local institutional review board and Canadian Health Protection Branch approval for a phase I clinical trial which it is hoped will extend our understanding of the behavior of gene marked hematopoietic progenitor cells in vivo. In this trial gene marked autologous marrow cells will be reinfused into volunteer patients undergoing myeloablative treatment for multiple myeloma. In this paper we describe the background to our ongoing trial and provide a trial outline.",
author = "Stewart, {Alexander Keith} and Prince, {H. Miles} and Dub{\'e}, {Ian D.}",
year = "1996",
month = "3",
language = "English (US)",
volume = "17",
pages = "175--184",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Background and Update to a Phase I Trial of Stem Cell Gene Marking in Multiple Myeloma

AU - Stewart, Alexander Keith

AU - Prince, H. Miles

AU - Dubé, Ian D.

PY - 1996/3

Y1 - 1996/3

N2 - Attractive target cells in gene transfer approaches to cancer treatment are pluripotent hematopoietic stem cells (HSCs) because of their high proliferative potential, self renewal and the wide systemic distribution of their progeny. A retroviral-mediated approach to gene transfer into HSCs is currently favored because the transduced gene is permanently integrated into the genome of the target cell resulting in the long-term stable expression of the gene product. Unfortunately, this approach requires that the target cell be in cycle and thus retroviral transduction of normally quiescent HSCs generally occurs at low efficiency. In previous work we have demonstrated that reinfused genetically marked long term bone marrow culture cells contribute significantly to long term hematopoiesis in a canine model. If also true in humans, such experiments suggest that bone marrow cells could be removed, transduced with a retroviral vector carrying a gene of known therapeutic effect and reinfused into the autologous recipient with minimal toxicity. The demonstration of successful long term gene transfer in humans would be an important prelude to therapeutic trials using genetically modified cells. To proceed in this new direction, important biological questions about the safety and feasibility of treatment with gene marked cells must first be addressed. We have therefore obtained local institutional review board and Canadian Health Protection Branch approval for a phase I clinical trial which it is hoped will extend our understanding of the behavior of gene marked hematopoietic progenitor cells in vivo. In this trial gene marked autologous marrow cells will be reinfused into volunteer patients undergoing myeloablative treatment for multiple myeloma. In this paper we describe the background to our ongoing trial and provide a trial outline.

AB - Attractive target cells in gene transfer approaches to cancer treatment are pluripotent hematopoietic stem cells (HSCs) because of their high proliferative potential, self renewal and the wide systemic distribution of their progeny. A retroviral-mediated approach to gene transfer into HSCs is currently favored because the transduced gene is permanently integrated into the genome of the target cell resulting in the long-term stable expression of the gene product. Unfortunately, this approach requires that the target cell be in cycle and thus retroviral transduction of normally quiescent HSCs generally occurs at low efficiency. In previous work we have demonstrated that reinfused genetically marked long term bone marrow culture cells contribute significantly to long term hematopoiesis in a canine model. If also true in humans, such experiments suggest that bone marrow cells could be removed, transduced with a retroviral vector carrying a gene of known therapeutic effect and reinfused into the autologous recipient with minimal toxicity. The demonstration of successful long term gene transfer in humans would be an important prelude to therapeutic trials using genetically modified cells. To proceed in this new direction, important biological questions about the safety and feasibility of treatment with gene marked cells must first be addressed. We have therefore obtained local institutional review board and Canadian Health Protection Branch approval for a phase I clinical trial which it is hoped will extend our understanding of the behavior of gene marked hematopoietic progenitor cells in vivo. In this trial gene marked autologous marrow cells will be reinfused into volunteer patients undergoing myeloablative treatment for multiple myeloma. In this paper we describe the background to our ongoing trial and provide a trial outline.

UR - http://www.scopus.com/inward/record.url?scp=0345984202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345984202&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0345984202

VL - 17

SP - 175

EP - 184

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 1

ER -